Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO 2) Study

Australian and New Zealand Journal of Medicine

Volumn 28, Issue 4, 1998, Pages 551-554

  White, Harvey D ^a,b   Ellis, Christopher J ^c   French, John K ^a   Aylward, Philip ^d  

^a GREEN LANE HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Direct thrombin inhibitors; Heparin; Hirudin; Myocardial infarction; Thrombolytic therapy

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; HIRUDIN; HIRULOG; STREPTOKINASE; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART REINFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MORTALITY; REVIEW;

EID: 7344266326     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1998.tb02109.x     Document Type: Review

References (17)

1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
2. Granger CB, Hirsh J, Califf RM et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I Trial. Circulation 1996; 93: 870-8.
3. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
4. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
5. Neuhaus K-L, v. Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994; 90: 1638-42.
6. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
7. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 1996; 94: 911-21.
8. Simes RJ, Granger CB, Antman EM, Califf RM, Braunwald E, Topol EJ. Impact of hirudin versus heparin on mortality and (re)infarction in patients with acute coronary syndromes: a prospective metaanalysis of the GUSTO-IIb and TIMI 9b Trials (Abstr.). Circulation 1996; 94 (Suppl. I): I-430-I-430.
9. Metz BK, Granger CB, White HD, Simes J, Topol EJ. Streptokinase and hirudin reduces death and reinfarction in acute myocardial infarction compared with Streptokinase and heparin: results from GUSTO IIb (Abstr.). Circulation 1996; 94 (Suppl. I): I-430-I-430.
10. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-25.
11. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23: 993-1003.
12. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987; 76: 142-54.
13. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation: a pilot study. Circulation 1997; 96: 769-77.
14. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-9.
15. White HD, Aylward PE, Frey M, Adgey AAJ, Nair R, Hillis WS et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997; 96: 2155-61.
16. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation 1995; 91: 1923-8.
17. Zoldhelyi P, Janssens S, Lefevre G, Collen D, Van de Werf F, for the GUSTO 2A Investigators. Effects of heparin and hirudin (CGP 39393) on thrombin generation during thrombolysis for acute myocardial infarction (Abstr.). Circulation 1995; 92 (Suppl. I): I-740-I-740.